Skip to content

PanACEA

  • Contact us
  • Twitter
  • News
  • About Us
    • Mission
    • History
    • Governance
    • Donors
    • Scientific Network
  • Tuberculosis
    • Impact
    • Treatment
    • Drug development
  • Clinical Studies
    • Trial Design
    • PanACEA Studies
    • Vision for future Studies
  • Capacity Development

Final PanACEA I Meeting in Alpbach, Austria

On January 25 – 28 the final PanACEA I meeting was held in Alpbach, Austria. PanACEA members of 11 countries (Belgium, Gabon, Germany, Great Britain, Kenya, Mozambique South Africa, Tanzania, The Netherlands, Uganda, and Zambia) attended the meeting. The newest results of the clinical studies, master and PhD studies and capacity development updates were presented.…

Read more Final PanACEA I Meeting in Alpbach, Austria

PanACEA in “World TB Day 2014 – Reach the 3 Million”

On March 24, 2014, Michael Hoelscher (LMU) presented “Advances in New TB Drug Development”, Tim McHugh (UCL) “Approaches to Monitoring Therapy” and Patrick Phillips (MRC CTU) “Drug Resistance vs. Drug Sensitive Trials “ at the “World TB Day – Reach the 3 Million” in London (www.who.int/campaigns/tb-day/2014/en). This conference, which was a joint venture between University…

Read more PanACEA in “World TB Day 2014 – Reach the 3 Million”

MAMS STUDY: Enrolment is Now Completed

On March 24 (on World TB Day), the MAMS TB-01 Study has completed enrolment ahead of schedule! We congratulate and thank everybody in achieving this goal prior to the target cut-off date of 31 March 2014. 365 patients have been enrolled in 4 South African and 3 Tanzanian sites.

Read more MAMS STUDY: Enrolment is Now Completed

MAMS study has completed first interim analysis

PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics aims to develop TB regimens that significantly shorten treatment duration, funded by EDCTP. The consortium’s most recent phase IIb study (MAMS-TB-01) uses an innovative adaptive clinical trial design that allows the efficient evaluation of multiple regimens by incorporating interim analyses that allow for the early…

Read more MAMS study has completed first interim analysis

Best Practices Awards Recognize Excellence in Clinical IT

Clinical Ink, in collaboration with PanACEA, received an award for their SureSource platform, a tablet-based system that allows onsite capturing

Read more Best Practices Awards Recognize Excellence in Clinical IT

PanACEA in Lancet

PanACEA investigators collaborate on comprehensive TB drug development review for Lancet Infectious Diseases special issue for World TB Day. http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2813%2970328-1/fulltext#

Read more PanACEA in Lancet

PanACEA in the WHO Global Tuberculosis Report

Last fall, the World Health Organization (WHO) published the latest global report on tuberculosis (TB). It provides a comprehensive and up-to-date assessment of the TB epidemic and of the progress made in TB prevention, care and control at global, regional and country level, using data reported by 197 countries and territories that account collectively for…

Read more PanACEA in the WHO Global Tuberculosis Report

MAMS study sites rapidly enrolling patients

PanACEA is excited to announce that all seven participating sites in the MAMS study

Read more MAMS study sites rapidly enrolling patients

The 5th Annual PanACEA Meeting

The 5th Annual PanACEA Meeting has been held on Ile de Gorée / Dakar, Senegal from 19-21 Oct 2013, just preceeding the 7th EDCTP Forum. Inspite of a couple of logistical challenges with colleagues travelling from all corners of Africa, Europe and the US to Gorée island the meeting has been a great success. PanACEA…

Read more The 5th Annual PanACEA Meeting

Quintiles

Read more Quintiles

Posts navigation

← Older posts
Newer posts →
© PanACEA
  • edctp
  • European Union
  • This project is part of the
    EDCTP2 programme supported
    by the European Union

  • Contact us
  • Twitter